e-learning
resources
European Respiratory Review
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Albera C.
Source:
Eur Respir Rev 2011; 20: 195-200
Journal Issue:
September 2011 - 20 (121)
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Albera C.. Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev 2011; 20: 195-200
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The six minute walking test: Clinical predictors of survival in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The latest insights in exercise testing and physical inactivity
Year: 2013
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 25: 96-103
Year: 2005
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Source: Eur Respir J 2013; 41: 262-269
Year: 2013
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Correlation of composite physiologic index with 6-minute walk test variables in patients with idiopathic interstitial pneumonias
Source: International Congress 2016 – Clinical exercise physiology in health and disease
Year: 2016
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Clinical predictors of pulmonary hypertension in sarcoidosis
Source: Eur Respir J 2008; 32: 296-302
Year: 2008
Sex differences in physiological progression of idiopathic pulmonary fibrosis
Source: Eur Respir J 2008; 31: 1183-1188
Year: 2008
Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Pulmonary hypertension in idiopathic pulmonary fibrosis: correlation to pulmonary function and exercise parameters
Source: Eur Respir J 2007; 30: Suppl. 51, 607s
Year: 2007
Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pulmonary rehabilitation in idiopathic pulmonary fibrosis: Predictors of adherence and exercise improvement
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013
A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 1067-1072
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept